Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile ...

Data from the Phase Ia/b study demonstrated that SAT-3247 was well-tolerated and safe with a desirable PK profile.

Detailed price information for Satellos Bioscience Inc (MSCLF) from The Globe and Mail including charting and trades.

Capricor Therapeutics has presented positive long-term data from its HOPE-2 clinical trial at the 2025 Muscular Dystrophy Association Conference, indicating that its leading treatment, deramiocel, can ...

Kye Pharmaceuticals ("Kye") announced today that Health Canada has approved AGAMREE® (vamorolone) for the treatment of ...

Entrada Therapeutics (NASDAQ:TRDA) said on Monday that it has received approval from the U.K.'s Medicines and Healthcare Products Regulatory Agency and the Research Ethics Committee to begin its ...

Health Canada has approved Santhera Pharmaceuticals’ Agamree (vamorolone) drug for treating Duchenne muscular dystrophy (DMD) ...

Tevard Biosciences Inc. has presented new preclinical data on the use of therapeutic suppressor tRNAs (suptRNAs) for the treatment of Duchenne muscular dystrophy (DMD) and dilated cardiomyopathy (DCM) ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including novel gene ...